<DOC>
	<DOCNO>NCT02753088</DOCNO>
	<brief_summary>The objective clinical study medicinal product medical use : compare efficacy safety generic drug BCD-063 Copaxone®-Teva patient relapsing-remitting multiple sclerosis . Period clinical study medicinal product medical use : June 10 , 2013 March 23 , 2016 . Number patient , involve study medicinal product medical use : 158 patient .</brief_summary>
	<brief_title>Efficacy Safety BCD-063 Copaxone-Teva Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Previously diagnose multiple sclerosis ( MS , McDonald criterion 2005 ) ; Disease , 1 year prior inclusion ; Presence 1 relapse previously OR least 1 Gd+ lesion T1 regimen ; EDSS 05,5 ; Absence exacerbation 4 week prior inclusion ; Readiness patient ( gender ) use reliable method contraception ( least 1 barrier method combination : spermicide , intrauterine device/oral contraceptive ) Secondary progressive primary progressive form multiple sclerosis ; Other disease ( except multiple sclerosis ) , may affect assessment severity symptom underlie disease : mask , amplify , modify symptom underlie disease cause clinical manifestation change data laboratory instrumental method investigation similar multiple sclerosis ; Any acute chronic infection acute stage ; Verified HIV , hepatitis B C , syphilis ; Metabolic abnormality ( disorder ) , manifest : 1. raise general level creatinine 2 time upper limit normal range ; 2. increase transaminase ( ALT , AST ) gammaglutamyltransferase 2.5 time upper limit normal range ; Violation bone marrow function reduce total number leukocytes &lt; 3000 /mcl , platelet count &lt; 125000 /mcl , hemoglobin concentration reduction , &lt; 100 g / l ; EDSS &gt; 5,5 point ; Liver disease stage decompensation ; Congestive heart failure , control drug therapy angina arrhythmia ; Pregnancy , breastfeed plan pregnancy study period ; Use time prior study drug modify multiple sclerosis : interferon beta1a , interferon beta1b , glatiramer acetate , azathioprine , corticosteroid immunomodulators ( except treat exacerbation corticosteroid ) , drug monoclonal antibody , cytotoxic / immunosuppressive drug , include , limited drug : mitoxantrone , cyclophosphamide , cyclosporine , fingolimod , cladribine ; total lymphoid irradiation system ; System ( IV , oral ) corticosteroid within 30 day prior screen visit ; Intolerance allergy glatiramer acetate , mannitol component BCD063 preparation Copaxone®Teva ; History drug addiction , alcoholism abuse drug ; Contraindications MRI ( gadolinium allergic intolerant close space , renal failure , may interfere removal gadolinium acute chronic renal failure ) ; Any malignancy , include anamnesis ; Vaccination within 4 week prior study entry ( prior randomization ) ; Participation clinical trial within 30 day prior screen simultaneous participation clinical trial ; Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Equivalence</keyword>
	<keyword>BCD-063</keyword>
	<keyword>Copaxone-Teva</keyword>
</DOC>